Following Amgen’s January launch of its Stelara biosimilar (Wezlana), at least five other ustekinumab biosimilars have stepped up to the plate, with a licensing dates of February 21 to March 7. Biocon Biologics announced that Yesintek is now available for prescription. Partners Samsung Bioepis and Sandoz launched Pyzchiva. Alvotech and Teva launched Selarsdi on February … Continue reading A New Wave of Ustekinumab Biosimilar Launches, Discounted up to 90%